365 related articles for article (PubMed ID: 31788752)
1. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
[TBL] [Abstract][Full Text] [Related]
2. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
[TBL] [Abstract][Full Text] [Related]
4. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
[TBL] [Abstract][Full Text] [Related]
5. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
8. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
9. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
10. Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
Zhang H; Xiao X; Luan S; Li X; Sun S; Yuan Y
Saudi Med J; 2024 May; 45(5):481-489. PubMed ID: 38734428
[TBL] [Abstract][Full Text] [Related]
11. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
13. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
14. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
15. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
[TBL] [Abstract][Full Text] [Related]
17. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
18. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
[TBL] [Abstract][Full Text] [Related]
20. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
Lu H; Liu JF; Rong Y; Liu XB; Wang Y
J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]